CVS Health Corp. (0HRS)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 94.30 |
|---|---|
| 52-week range | 69.18 – 112.00 |
| Return, 1 month / 3 months | +7.7% / −11.3% |
| Return, 1 year / 3 years | +15.3% / +50.0% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 30.2% |
| Worst drawdown (1 year) | -22.7% |
| Average daily value traded | 0.63M USD |
| Dividend yield | 1.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CVS Health is a healthcare company based in the United States. It runs retail pharmacies that fill prescriptions and sell health and personal care products to consumers, and it provides pharmacy benefit management services to employers and health plans. Through its insurance arm it offers health coverage, and it also operates walk-in medical clinics and provides pharmacy services to long-term care facilities. Its customers include individual patients, employers, insurers and government health programmes.
On this site CVS Health Corp. appears as a stock on the London Exchange (UK), code 0HRS, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CVS Health Corp. (0HRS) trades on the London Exchange in UK. It last closed at USD 94.30 on 21 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,653 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 15.3% and over the last three months it fell 11.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.5% | ||
| From 52-week high | -14.1% | ||
| Momentum | 53 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -11.3% | ||
| 6-month return | 21.5% | ||
| 12-month return, skipping the last month | 7.0% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.7% | ||
| Liquidity | 48 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.63M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 47 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.4% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.7% |
|---|---|
| 1 month | +7.7% |
| 3 months | −11.3% |
| 6 months | +21.5% |
| 1 year | +15.3% |
| 3 years | +50.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 91.72 / 88.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 3.42 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Jan 2026 | USD 0.6650 |
| 22 Oct 2025 | USD 0.6650 |
| 21 Jul 2025 | USD 0.6650 |
| 17 Apr 2025 | USD 0.6650 |
| 22 Jan 2025 | USD 0.6650 |
| 21 Oct 2024 | USD 0.6650 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.